TITLE

FDA actions

PUB. DATE
December 2010
SOURCE
Internal Medicine Alert;12/15/2010 Clinical Briefs, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the move of the Food and Drug Administration (FDA) which approved fingolimod, the first oral drug for the treatment of relapsing forms of multiple sclerosis in the U.S.
ACCESSION #
57803285

 

Related Articles

  • Acorda Therapeutics wins FDA approval for multiple sclerosis.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Betaseron near formal approval.  // Inside MS;Summer93, Vol. 11 Issue 2, p5 

    Reports on the pending Food and Drug Administration (FDA) approval for the drug Interferon veta1b, better known as betaseron for use in relapsing-remitting multiple sclerosis (MS). Results of a study of 388 MS patients treated with betaseron; Additional reviews conducted by the FDA to answer...

  • The MS community responds.  // Inside MS;Summer93, Vol. 11 Issue 2, p6 

    Features a letter to Food and Drug Administration (FDA) Commissioner David A. Kessler from Carolyn Hathorn who represent the opinion of hundreds of men and women advocating the use of the drug, betaseron, in treating patients with multiple sclerosis. Petition for FDA approval of the drug;...

  • Betaseron: Getting the facts out.  // Inside MS;Summer93, Vol. 11 Issue 2, p7 

    Reports on the Food and Drug Administration's March 19,1993 announcement on the possibility of using the drug betaseron for treatment of multiple sclerosis patients. National and local news media report; Handouts provided by the staff of the National Multiple Sclerosis Society staff.

  • FDA's advisory panel recommended approval for Avonex.  // Inside MS;Winter/Spring96, Vol. 14 Issue 1, p5 

    Reports on the Food and Drug Administration's expert advisory recommendation to approve the marketing of Biogen's Avonex brand of interferon beta-1a drug. Treatment of relapsing-remitting forms of multiple sclerosis (MS); Background information; Implications; Plans and expectations; Contact...

  • FDA decision on Rebif.  // Inside MS;Spring99, Vol. 17 Issue 2, p34 

    Reports result of the clinical trial on Rebif, an interferon beta-1a drug for multiple sclerosis (MS) attacks. Effects of the drug; United States Food and Drug Administration (FDA) review.

  • Betaseron for secondary-progressive MS?  // Inside MS;Spring99, Vol. 17 Issue 2, p34 

    Reports on the result of a European trial of Betaseron in people with secondary-progressive multiple sclerosis (MS). Coverage of the United States Food and Drug Administration (FDA); Review of the FDA.

  • News flash: Novantrone is near approval for MS.  // Inside MS;Spring2000, Vol. 18 Issue 2, p16 

    Reports that a United States Food and Drug Administration (FDA) advisory committee recommended on January 28, 2000 that the FDA approve Novantrone for secondary-progressive multiple sclerosis (MS). Results of clinical trials of Novantrone; Significant side effects of the drug; Background...

  • News.  // Inside MS;Winter2001, Vol. 19 Issue 1, p24 

    Presents news briefs about the treatment and prevention of multiple sclerosis in the United States (U.S.) as of January 2001. Approval on the drug Novantrone by the U.S. Food and Drug Administration; Capability of the drug Copaxone to delay disability; Mechanism of action of Avonex as...

  • Rebif [in Context]. King, Martha // Inside MS;Summer2002, Vol. 20 Issue 3, p45 

    Offers a perspective on Rebif, a drug approved by the U.S. Food and Drug Administration for multiple sclerosis (MS) in March 2002. Basis of the approval; Remarks from internationally renowned neurologists on the drug; Distinction of Rebif from other MS drugs. INSET: A note on Novatrone.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics